Repotrectinib is Used for treating locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adult patients. It was first introduced by Bristol Myers Squibb Co in its drug Augtyro on Nov 15, 2023.

Repotrectinib Patents

Given below is the list of patents protecting Repotrectinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Augtyro	US10294242	Diaryl macrocycle polymorph	Jul 05, 2036	Bristol
Augtyro	US11452725	Chiral diaryl macrocycles and uses thereof	Jul 24, 2036	Bristol
Augtyro	US9714258	Diaryl macrocycles as modulators of protein kinases	Jan 23, 2035	Bristol

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳